Further on, to assess the capacity of the UBE2I assay to differentiate between ccRCC and normal samples, receiver operating characteristic (ROC) curve analyses were performed, using the IHC data of the UBE2I nucleus as an independent classifier. This evidence concerns the gene UBE2I and nonpapillary renal cell carcinoma.